Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jan;69(1):113-9.
doi: 10.1136/ard.2008.094623.

Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial

X Chevalier  1 , J Jerosch, P Goupille, N van Dijk, F P Luyten, D L Scott, F Bailleul, K Pavelka
Affiliations
Randomized Controlled Trial

Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial

X Chevalier et al. Ann Rheum Dis. 2010 Jan.

Abstract

Objectives: The primary objective was to compare a single, 6 ml, intra-articular injection of hylan G-F 20 with placebo in patients with symptomatic knee osteoarthritis. The safety of a repeat injection of hylan G-F 20 was also assessed.

Methods: Patients with primary osteoarthritis knee pain were randomly assigned to arthrocentesis plus a 6 ml intra-articular injection of either hylan G-F 20 or placebo in a prospective, double-blind (one injector/one blinded observer) study.

Results: were evaluated at 4, 8, 12, 18 and 26 weeks post-injection. The primary outcome criterion was change from baseline over 26 weeks in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index A pain. Secondary outcome measures included WOMAC A1 and C, patient global assessment (PGA) and clinical observer global assessment (COGA) and Outcome Measures in Rheumatology, Osteoarthritis Research Society International responder rates. A 4-week, open, repeat treatment phase evaluated safety only. Results: A total of 253 patients (Kellgren-Lawrence grade II or III) was randomly assigned. Patients receiving hylan G-F 20 experienced statistically significantly greater improvements in WOMAC A pain scores (-0.15, SE 0.076, p = 0.047), and several of the secondary outcome measures (WOMAC A1, PGA and COGA), than patients receiving placebo. There was no difference between the safety results of the two groups. No increased risk of local adverse events was observed in the open, repeat treatment phase.

Conclusions: This placebo-controlled study demonstrated that, in patients with knee osteoarthritis, a single 6 ml intra-articular injection of hylan G-F 20 is safe and effective in providing statistically significant, clinically relevant pain relief over 26 weeks, with a modest difference versus placebo.

Trial registration: ClinicalTrials.gov NCT00131352.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Declared. XC, JJ and PG have been reimbursed by Genzyme Biosurgery, the manufacturer of hylan G-F 20, for attending symposia and have also received speaker fees. JJ has received research funds from Genzyme Biosurgery. FB is an employee of Genzyme Biosurgery working in the Clinical Research and Medical Affairs Departments. NvD, FPL, DLS and KP have no conflicts of interest. All authors actively participated in the conduct of this trial and in its analysis and interpretation.

Figures

Figure 1
Figure 1
Study flow chart. AE, adverse event; ITT, intent-to-treat.
Figure 2
Figure 2
Mean change from baseline in the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index A (pain), intent-to-treat population.
See this image and copyright information in PMC

References

    1. Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004;427(Suppl):S6–15 - PubMed
    1. Schurz J, Ribitsch V. Rheology of synovial fluid. Biorheology 1987;24:385–99 - PubMed
    1. Mazzucco D, McKinley G, Scott RD, et al. Rheology of joint fluid in total knee arthroplasty patients. J Orthop Res 2002;20:1157–63 - PubMed
    1. Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology 2007;44:59–74 - PubMed
    1. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;19(2):CD005321. - PMC - PubMed

Publication types

MeSH terms

Associated data